The Goldline Pharmaceutical IPO is a closed SME Bookbuilding offer (Fresh capital only) that opened on 12 May 2026. The Goldline Pharmaceutical IPO closed on 14 May 2026, with an issue price of ₹43 per share. The Goldline Pharmaceutical IPO has a face value of ₹10 and a lot size of 3,000 shares. The Goldline Pharmaceutical IPO is listed on 19 May 2026. The Goldline Pharmaceutical IPO allotment was scheduled for 15 May 2026.
On the financial front, the Goldline Pharmaceutical IPO reported revenue of ₹28 crore for 31 Mar 2025, compared with ₹24 crore for 31 Mar 2024. The Goldline Pharmaceutical IPO PAT was ₹3 crore against ₹2 crore. The Goldline Pharmaceutical IPO EBITDA stood at ₹6 crore with a 20.79% margin. The Goldline Pharmaceutical IPO net worth as of 31 Mar 2025 was ₹10 crore.
Always verify The Goldline Pharmaceutical IPO details and GMP data with the official offer document before investing in the Goldline Pharmaceutical IPO.
Financial Summary
Amount in ₹ Crore
Metric
31 Mar 2025
31 Mar 2024
31 Mar 2023
Total Assets
26
23
19
Revenue
28
24
20
PAT
3
2
0
EBITDA
6
4
2
Net Worth
10
8
6
Reserves
2
4
2
Total Borrowing
11
11
11
Goldline Pharmaceutical IPO Financials FAQs
Revenue of Goldline Pharmaceutical (Amount in ₹ Crore) — 31 Mar 2025: 28; 31 Mar 2024: 24; 31 Mar 2023: 20. Profit after tax (PAT) — 31 Mar 2025: 3; 31 Mar 2024: 2; 31 Mar 2023: 0.
EBITDA of Goldline Pharmaceutical (Amount in ₹ Crore) — 31 Mar 2025: 6; 31 Mar 2024: 4; 31 Mar 2023: 2. The EBITDA margin is 20.79%.
Total assets — 31 Mar 2025: 26; 31 Mar 2024: 23; 31 Mar 2023: 19. Net worth — 31 Mar 2025: 10; 31 Mar 2024: 8; 31 Mar 2023: 6. Reserves & surplus — 31 Mar 2025: 2; 31 Mar 2024: 4; 31 Mar 2023: 2. (Amount in ₹ Crore)
Total borrowing of Goldline Pharmaceutical (Amount in ₹ Crore) — 31 Mar 2025: 11; 31 Mar 2024: 11; 31 Mar 2023: 11. Debt-to-equity ratio: 1.50.
The financials shown for Goldline Pharmaceutical IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.
